| Antitumor activity of thalidomide in refractory multiple myeloma S Singhal, J Mehta, R Desikan, D Ayers, P Roberson, P Eddlemon, ... New England Journal of Medicine 341 (21), 1565-1571, 1999 | 3641 | 1999 |
| Initial genome sequencing and analysis of multiple myeloma MA Chapman, MS Lawrence, JJ Keats, K Cibulskis, C Sougnez, ... Nature 471 (7339), 467-472, 2011 | 1694 | 2011 |
| Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America DM Weber, C Chen, R Niesvizky, M Wang, A Belch, EA Stadtmauer, ... New England Journal of Medicine 357 (21), 2133-2142, 2007 | 1616 | 2007 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1584 | 2015 |
| Idecabtagene vicleucel in relapsed and refractory multiple myeloma NC Munshi, LD Anderson Jr, N Shah, D Madduri, J Berdeja, S Lonial, ... New England Journal of Medicine 384 (8), 705-716, 2021 | 1465 | 2021 |
| Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma N Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ... New England Journal of Medicine 380 (18), 1726-1737, 2019 | 1429 | 2019 |
| Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised … SV Rajkumar, S Jacobus, NS Callander, R Fonseca, DH Vesole, ... The lancet oncology 11 (1), 29-37, 2010 | 1195 | 2010 |
| Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ... Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011 | 1125 | 2011 |
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo, MS Lawrence, D Auclair, ... Cancer cell 25 (1), 91-101, 2014 | 1100 | 2014 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
| A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma S Jagannath, B Barlogie, J Berenson, D Siegel, D Irwin, PG Richardson, ... British journal of haematology 127 (2), 165-172, 2004 | 977 | 2004 |
| Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group P Sonneveld, H Avet-Loiseau, S Lonial, S Usmani, D Siegel, ... Blood, The Journal of the American Society of Hematology 127 (24), 2955-2962, 2016 | 943 | 2016 |
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma DS Siegel, T Martin, M Wang, R Vij, AJ Jakubowiak, S Lonial, S Trudel, ... Blood, The Journal of the American Society of Hematology 120 (14), 2817-2825, 2012 | 809 | 2012 |
| Total therapy with tandem transplants for newly diagnosed multiple myeloma B Barlogie, S Jagannath, KR Desikan, S Mattox, D Vesole, D Siegel, ... Blood, The Journal of the American Society of Hematology 93 (1), 55-65, 1999 | 794 | 1999 |
| Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib PG Richardson, H Briemberg, S Jagannath, PY Wen, B Barlogie, ... J Clin Oncol 24 (19), 3113-3120, 2006 | 784 | 2006 |
| Toxic acute tubular necrosis following treatment with zoledronate (Zometa) GS Markowitz, PL Fine, JI Stack, CL Kunis, J Radhakrishnan, W Palecki, ... Kidney international 64 (1), 281-289, 2003 | 472 | 2003 |
| Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study PG Richardson, DS Siegel, R Vij, CC Hofmeister, R Baz, S Jagannath, ... Blood, The Journal of the American Society of Hematology 123 (12), 1826-1832, 2014 | 448 | 2014 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities R Desikan, B Barlogie, J Sawyer, D Ayers, G Tricot, A Badros, M Zangari, ... Blood, The Journal of the American Society of Hematology 95 (12), 4008-4010, 2000 | 409 | 2000 |
| International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma M Dimopoulos, E Terpos, RL Comenzo, P Tosi, M Beksac, O Sezer, ... Leukemia 23 (9), 1545-1556, 2009 | 401 | 2009 |
